|Articles|March 1, 2001

Optimizing Quality of Care and Cost Effectiveness in the Treatment of Overactive Bladder
Volume 7
Issue 2 Suppl

Continuing Medical / Pharmacy Education Quiz

Download PDF: Continuing Medical / Pharmacy Education Quiz

Articles in this issue

over 25 years ago

Article

Participating Faculty

over 25 years ago

Article

Introduction

over 25 years ago

Article

Overactive Bladder: Optimizing Quality of Care

over 25 years ago

Article

Cost Effectiveness and Quality of Life Considerations in the Treatment of Patients with Overactive Bladder

over 25 years ago

Article

Selected Abstracts

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Continuing Medical / Pharmacy Education Quiz

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Continuing Medical / Pharmacy Education Quiz

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain